A new generation drug tested on yeast extends their lifespan and slows down the aging process by affecting the main growth pathway TOR (Target of Rapamycin). Research has revealed the important role of agmatinases enzymes, which help keep this pathway in balance and thus contribute to healthy aging. Agmatine, a substance derived from the amino acid arginine, is produced by diet and gut microbes, suggesting that nutrition and the gut microbiome can significantly influence the aging process. Polyamines, which are formed during the activity of agmatinases, have an important role in cell metabolism, DNA stability and recycling of damaged structures. The authors of the study caution that agmatine supplementation may only be beneficial under certain conditions, as its effects depend on properly functioning metabolic pathways and may also contribute to certain diseases. This research brings a new level of understanding of the metabolic control of aging that could also be relevant to humans. The results indicate the drug's potential not only in fighting cancer, but also in slowing cell aging[1].